Torendo - Instructions For The Use Of Tablets, Reviews, Price, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Torendo

Torendo: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Torendo

ATX code: N.05. AX08

Active ingredient: risperidone (risperidone)

Manufacturer: Krka, dd, Novo mesto, JSC (Slovenia), Krka-RUS, LLC (Russia)

Description and photo update: 2018-21-11

Prices in pharmacies: from 156 rubles.

Buy

Torendo is an antipsychotic drug (neuroleptic).

Release form and composition

Dosage form Torendo - film-coated tablets: biconvex, oval, with a risk on one side; 1 mg - almost white or white, 2 mg - light orange, 3 mg - yellow, 4 mg - light green (in blisters of 10 pcs., in a cardboard box of 2, 3 or 6 blisters).

Composition of 1 film-coated tablet:

• active substance: risperidone - 1 mg, 2 mg, 3 mg or 4 mg;
• auxiliary components (1/2/3/4 mg, respectively): magnesium stearate - 1.6 / 1.6 / 1.6 / 1.6 mg; sodium lauryl sulfate - 2.1 / 2.1 / 2.1 / 2.1 mg; colloidal silicon dioxide - 0.7 / 0.7 / 0.7 / 0.7 mg; croscarmellose sodium - 8.4 / 8.4 / 8.4 / 8.4 mg; microcrystalline cellulose - 41/41/41/41 mg; cellactose (cellulose powder - 25%, alpha-lactose monohydrate - 75%) - 155.2 / 154.2 / 153.2 / 152, 2 mg;
• film shell (1/2/3/4 mg, respectively): opadry 03H28758 white [propylene glycol - 5%, talc - 7%, titanium dioxide (E171) - 16%, hypromellose - 72%] - 7 / 6.92 / 6.98 / 6.99 mg; additionally for 2 mg tablets: iron dye red oxide (E172) - 0.02 mg, iron dye yellow oxide (E172) - 0.06 mg; for tablets of 3 mg: quinoline yellow dye (E104) - 0.02 mg; for 4 mg tablets: indigo carmine (E132) - 0.002 mg, quinoline yellow dye (E104) - 0.008 mg.

Pharmacological properties

Pharmacodynamics

Risperidone is a selective monoaminergic antagonist with high affinity for dopamine D ₂ receptors and serotonin 5-HT ₂ receptors. It binds to α ₁ -adrenergic receptors and to a lesser extent to α ₂ -adrenergic receptors and H ₁ -histamine receptors. Does not possess tropism for cholinergic receptors. Risperidone reduces the productive symptoms of schizophrenia, causes less suppression of motor activity, and induces catalepsy to a lesser extent in comparison with classical antipsychotics.

By means of a balanced central antagonism to dopamine and serotonin, the likelihood of developing extrapyramidal disorders is reduced and the therapeutic effect of the drug is expanded to cover the affective and negative symptoms of schizophrenia.

Pharmacokinetics

Characteristics of risperidone:

• absorption: completely absorbed after oral administration, reaching C _max (maximum concentration in blood plasma) after 1-2 hours; absolute bioavailability is 70%; the relative bioavailability of risperidone tablets in comparison with the solution is 94%; food does not affect absorption, which allows Torendo to be used regardless of food intake; equilibrium concentration in most cases is achieved within 1 day; the equilibrium concentration of 9-hydroxyrisperidone (the main metabolite of risperidone) is reached within 4–5 days;
• distribution: quickly distributed in the body; the volume of distribution is 1-2 liters per 1 kg; binds to alpha1-acid glycoprotein and albumin in blood plasma; the connection of risperidone with proteins is 90%, 9-hydroxyrisperidone - 77%;
• metabolism: metabolized in the liver with the participation of the isoenzyme CYP2D6; 9-hydroxyrisperidone has a similar pharmacological activity; risperidone and 9-hydroxyrisperidone constitute the active antipsychotic fraction; isoenzyme CYP2D6 is susceptible to genetic polymorphism; against the background of intensive metabolism by the CYP2D6 isoenzyme, risperidone is rapidly converted to 9-hydroxyrisperidone, while with a weak metabolism by the CYP2D6 isoenzyme, this process is much slower; despite the fact that with intensive metabolism the concentration of risperidone is lower and the concentration of 9-hydroxyrisperidone is higher than against the background of a weak metabolism, the pharmacokinetics of the active antipsychotic fraction after taking one or several doses in both cases is similar; another way of its metabolism is N-dealkylation;conducted in vitro studies on human liver microsomes have shown that at clinically significant concentrations, the substance does not significantly inhibit the metabolism of drugs, the biotransformation of which occurs under the action of isoenzymes of the cytochrome P system₄₅₀ including CYP3A5, CYP3A4, CYP2E1, CYP2D6, CYP2C8 / 9/10, CYP2A6 and CYP1A2;
• excretion: after 7 days from the start of taking, 70% of the dose of Torendo is excreted through the kidneys (while the excretion of risperidone and 9-hydroxyrisperidone from the dose taken is 35–45%, the rest is inactive metabolites) and through the intestines (14%); with psychosis T _1/2 (half-life) is approximately 3 hours; T _{1/2 of} 9-hydroxyrisperidone and active antipsychotic fraction is 24 hours;
• linearity: the concentration of the agent in the blood plasma is directly proportional to the dose taken in the therapeutic dose range.

The concentration of the active antipsychotic fraction in the blood plasma in elderly patients after a single dose of risperidone increases by 43% (on average), T _1/2 - by 38%; clearance is reduced by 30%.

With renal failure, the plasma concentration increases and the clearance of the active antipsychotic fraction decreases by 60% (on average). At the same time, the concentration of risperidone in the blood plasma does not change, but the average concentration of its free fraction increases by 35%.

In children, the pharmacokinetics of risperidone, 9-hydroxyrisperidone and the active antipsychotic fraction are comparable to those in adults.

Gender, race or tobacco smoking has no obvious effect on the pharmacokinetics of risperidone and its active antipsychotic fraction.

Indications for use

• schizophrenia (therapy);
• manic episodes associated with bipolar disorder, moderate to severe (therapy);
• incessant aggression in dementia, the development of which was caused by Alzheimer's disease, moderate and severe, not amenable to non-pharmacological methods of correction, and at the risk of harming the patient to himself or to other persons (short-term therapy lasting no more than 42 days);
• incessant aggression in the structure of behavioral disorders in children over 13 years of age with mental retardation, against which, due to the severity of aggression or other destructive behavior, drug treatment is necessary. The use of drugs should be part of a comprehensive therapy program that includes psychological and educational activities. Torendo should be prescribed by a physician familiar with the treatment of behavioral disorders in children and adolescents, or a specialist in child neurology and child psychiatry (short-term symptomatic therapy lasting no more than 42 days).

Contraindications

Absolute:

• syndrome of glucose-galactose malabsorption, lactase deficiency, lactose intolerance (due to the content of lactose in Torendo);
• combined administration of paliperidone;
• body weight less than 50 kg in the treatment of persistent aggression in the structure of conduct disorder;
• childhood: therapy of schizophrenia, incessant aggression in the structure of conduct disorder - under 13 years old; treatment of manic episodes associated with bipolar disorder - under 10 years of age;
• individual intolerance to the components contained in the preparation.

Relative (diseases / conditions in the presence of which the appointment of Torendo requires caution):

• severe renal or hepatic impairment;
• cardiac muscle conduction disturbances, myocardial infarction, chronic heart failure (diseases of the cardiovascular system);
• risk factors for the development of stroke, thromboembolism of the venous vessels;
• disorders of cerebral circulation;
• hypovolemia and dehydration;
• diffuse Lewy body disease;
• Parkinson's disease;
• convulsions (including a history);
• high ambient temperature, dehydration, intense physical activity, combined intake of funds with anticholinergic activity (factors causing an increase in body temperature);
• the presence of hyperprolactinemia, suspected prolactin-dependent tumors;
• drug dependence or drug abuse;
• Reye's syndrome, cases of acute drug overdose, brain tumor, intestinal obstruction (the antiemetic effect of risperidone can mask the symptoms of these conditions);
• combined treatment with drugs that prolong the QT interval, electrolyte imbalance, bradycardia (conditions predisposing to the development of tachycardia of the "pirouette" type);
• combined use of benzodiazepines, antihistamines, opiates, ethanol (increased risk of sedation);
• old age in combination with cerebrovascular dementia;
• pregnancy.

Instructions for use of Torendo: method and dosage

Torendo tablets are taken orally, with or without food, 1 or 2 times a day.

Schizophrenia

Recommended dosage regimen:

• adults: on the first day - 2 mg; on the second day - it is possible to increase the dose by 2 times. After that, it is either kept at the same level, or corrected individually (if necessary). The optimal daily dose is 4 to 6 mg. Perhaps a slower increase and the appointment of smaller initial and maintenance doses in some cases. The use of more than 10 mg of Torendo per day has not been shown to be more effective in comparison with lower doses and may cause the development of extrapyramidal symptoms. Since the safety of doses exceeding 16 mg per day has not been studied, their appointment is not recommended;
• elderly patients: the initial dose is 0.5 mg 2 times a day. On an individual basis, it can be increased by 0.5 mg 2 times a day to 1-2 mg 2 times a day;
• children under 13 years of age: the initial dose is 0.5 mg once a day (in the morning or evening). After 24 hours (at least), if Torendo is well tolerated, it can be increased by 0.5-1 mg per day to the recommended dose of 3 mg per day, if necessary. Taking daily doses in excess of 3 mg does not demonstrate additional efficacy, but causes more side effects. The use of more than 6 mg of the drug per day has not been studied. In case of persistent drowsiness, it is recommended to prescribe ½ daily dose 2 times a day.

Manic episodes associated with bipolar disorder, moderate to severe

Recommended dosage regimen:

• adults: the initial dose is 2 mg per day, it is possible to increase it after 24 hours by 1 mg per day. The optimal daily dose in most cases is 1 to 6 mg per day. The use of more than 6 mg of Torendo per day has not been studied. As with any other symptomatic treatment, it is necessary to regularly evaluate and confirm the feasibility of continuing drug therapy;
• elderly patients: initial dose - 0.5 mg 2 times a day, its individual increase by 0.5 mg 2 times a day up to 1-2 mg 2 times a day is possible. Since the experience of using Torendo in patients of this age group is limited, it is important to exercise caution;
• children over 10 years of age: the initial dose is 0.5 mg per day (in the morning or evening), it is possible to increase it after 24 hours by 0.5-1 mg per day to 1-2.5 mg per day, if Torendo well tolerated by the patient. Additional efficacy is not observed when taking more than 2.5 mg of the drug per day, but the incidence of adverse reactions increases. The use of more than 6 mg of the drug per day has not been studied. In case of persistent drowsiness, it is recommended to prescribe ½ the daily dose.

Persistent aggression in moderate to severe Alzheimer's dementia

The initial dose is 0.25 mg 2 times a day, it is possible to increase it by 0.25 mg 2 times a day with an interval of 1 day (at least).

The optimal dose is 0.5 mg 2 times a day. In some cases, the effective dose may be 1 mg 2 times a day.

The duration of therapy should not exceed 42 days. During the treatment period, a frequent and regular assessment of the patient's condition is required to decide whether to continue taking Torendo.

At the beginning of dosing and, if necessary, increasing the dose, adequate dosage forms of the drug are used with the possibility of dosing at 0.25 mg.

Persistent aggression in the structure of conduct disorder in children from 13 years of age (or weighing 50 kg or more)

The initial dose is 0.5 mg per day in one dose, it is possible to increase it after 24 hours (at least) by 0.5 mg per day.

The optimal dose is 1 mg per day in one dose. For some patients, it is preferable to prescribe 0.5 mg of Torendo per day, others may need to increase the dose to 1.5 mg per day.

Long-term Torendo therapy should be carried out under the constant supervision of a physician.

Cancellation of Torendo

The drug is discontinued gradually, since abrupt cessation of high doses in very rare cases can lead to the development of withdrawal syndrome. Relapses of psychotic symptoms and the appearance of involuntary movements (dyskinesia, dystonia, akathisia) may also occur.

Switching from treatment with other antipsychotics

After starting Torendo, the dose of the other antipsychotic is gradually reduced. In the case of previous treatment with depot antipsychotic drugs, drug therapy is started instead of the next scheduled injection. It is important to periodically assess the need for continued use of drugs in this group.

Side effects

Possible adverse reactions (> 10% - very common;> 1% and 0.1% and 0.01% and <0.1% - rarely; <0.01% - very rare):

• laboratory and instrumental data: often - an increase in body weight, concentration of prolactin in the blood serum; infrequently - an increase in the concentration of cholesterol in the blood plasma, the activity of liver enzymes, body temperature, the number of eosinophils in the blood, the activity of creatine phosphokinase, a decrease in hematocrit, hemoglobin, the number of leukocytes in the blood, body weight, disturbance of the electrocardiogram and lengthening of the QT interval on it; rarely - an increase in the concentration of triglycerides in blood plasma, a decrease in body temperature;
• heart: often - tachycardia; infrequently - conduction disturbance, palpitations, sinus bradycardia, atrial fibrillation, bundle branch block, AV block (atrioventricular block); rarely - sinus arrhythmia;
• vessels: often - increased blood pressure; infrequently - rush of blood to the skin of the face, orthostatic or arterial hypotension; rarely - venous thrombosis, pulmonary embolism;
• blood and lymphatic system: infrequently - thrombocytopenia, anemia, neutropenia; rarely - agranulocytosis, granulocytopenia;
• nervous system: very often - headache, parkinsonism, drowsiness or sedation; often - dyskinesia, lethargy, dystonia, tremor, dizziness, akathisia; infrequently - paresthesia, dysgeusia, psychomotor hyperactivity, seizures, impaired attention, speech, movement, coordination, balance, cerebral ischemia, hypesthesia, tardive dyskinesia, postural dizziness, hypersomnia, dysarthria, transient ischemic attack, stroke, depressed level of consciousness, consciousness, lack of response to stimuli; rarely - head tremor, cerebrovascular disorders, diabetic coma, neuroleptic malignant syndrome;
• organ of vision: often - conjunctivitis, blurred vision; infrequently - photophobia, lacrimation, dry eyes, edema of the area around the eyes, discharge from the eyes, blurred vision, ocular hyperemia; rarely - movement disorder of the eyes, intraoperative syndrome of flabby iris, glaucoma, involuntary rotation of the eyeballs, decreased visual acuity;
• hearing and labyrinthine disorders: infrequently - tinnitus, ear pain;
• respiratory system, chest and mediastinal organs: often - pain in the larynx and pharynx, nasal congestion, cough, epistaxis, shortness of breath; infrequently - dysphonia, impaired airway patency, breathing, wet wheezing, pulmonary congestion, aspiration pneumonia, wheezing; rarely - hyperventilation, sleep apnea syndrome;
• gastrointestinal tract: often - toothache, stomach discomfort, dryness of the oral mucosa, dyspepsia, abdominal pain, nausea, constipation, diarrhea, vomiting; infrequently - flatulence, gastroenteritis, fecaloma, hypersalivation, fecal incontinence, gastritis, dysphagia; rarely - cheilitis, swelling of the tongue, lips, pancreatitis, intestinal obstruction;
• kidneys and urinary tract: often - enuresis; infrequently - pollakiuria, urinary incontinence, dysuria, urinary retention;
• skin and subcutaneous tissues: often - erythema, skin rash; infrequently - hyperkeratosis, dry skin, seborrheic dermatitis, alopecia, discoloration of the skin, acne, pruritus, skin lesions, eczema, urticaria; rarely - dandruff, toxicoderma; very rarely - Quincke's edema;
• musculoskeletal and connective tissue: often - muscle spasms, musculoskeletal pain, arthralgia, pain in the limbs, back; infrequently - joint stiffness, poor posture, joint swelling, neck pain, muscle weakness; rarely - rhabdomyolysis;
• endocrine system: rarely - glucosuria, impaired production of antidiuretic hormone;
• metabolism and nutrition: often - decreased / increased appetite; infrequently - hyperglycemia, polydipsia, anorexia, diabetes mellitus; rarely - hyperinsulinemia, water intoxication, hypoglycemia; very rarely, diabetic ketoacidosis;
• infectious and parasitic pathologies: often - infections of the ear, urinary tract, upper respiratory tract, sinusitis, bronchitis, flu, pneumonia; infrequently - onychomycosis, cystitis, infections of the respiratory tract, eyes, acarodermatitis, localized infections, otitis media, inflammation of the subcutaneous fat, tonsillitis, viral infections; rarely - chronic otitis media;
• general disorders and disorders at the injection site: often - chest pain, asthenia, peripheral or generalized edema, fatigue, pyrexia; infrequently - chills, chest discomfort, thirst, flu-like condition, sluggishness, feeling unwell, gait disturbance, swelling of the face; rarely - cold extremities, withdrawal syndrome, hypothermia;
• injuries: often - falling;
• immune system: infrequently - hypersensitivity; rarely - anaphylactic reactions;
• liver and biliary tract: rarely - jaundice;
• genitals and mammary gland: infrequently - discomfort and pain in the chest, vaginal discharge, menstrual disorders, ejaculation, gynecomastia, galactorrhea, erectile or sexual dysfunction, amenorrhea; rarely - discharge from the mammary glands, enlargement or engorgement of the mammary glands, delayed menstruation, priapism;
• perinatal and postpartum conditions: rarely - withdrawal syndrome in newborns;
• psyche: very often - insomnia; often - sleep disturbances, agitation, anxiety, depression; infrequently - nightmares, nervousness, lethargy, decreased libido, mania, confusion; rarely - flattening of affect, anorgasmia.

Overdose

The main symptoms: extrapyramidal disorders, arterial hypotension, tachycardia, sedation, drowsiness; rarely - convulsions, lengthening of the QT interval. In case of overdose against the background of the combined administration of risperidone with paroxetine, polymorphic ventricular tachycardia of the "pirouette" type was observed. In acute cases, it is important to consider the likelihood of an overdose from taking multiple drugs.

Therapy: Ensuring airway patency for adequate oxygenation and ventilation; gastric lavage (after intubation, if the patient is unconscious), taking activated charcoal and laxatives (if risperidone was taken no more than 1 hour ago). In order to timely diagnose a probable heart rhythm disorder, electrocardiogram monitoring begins as soon as possible. There is no symptomatic antidote; appropriate symptomatic treatment is carried out. In cases of vascular collapse and a decrease in blood pressure, intravenous infusion solutions and / or sympathomimetic agents are administered; with the development of severe extrapyramidal symptoms - anticholinergic drugs. Until the symptoms of intoxication completely disappear, careful medical supervision and monitoring of the electrocardiogram are required.

special instructions

Elderly patients with dementia receiving therapy with atypical antipsychotics showed increased mortality compared to the placebo group, as evidenced by the results of a meta-analysis of clinical trials. Mortality in patients taking Torendo or placebo was 4% and 3.1%, respectively. The average age of the deceased patients was 86 years. The cause of the increase in mortality has not yet been identified, and the extent to which the increase in mortality may be applicable to antipsychotic drugs, and not to the characteristics of this age group, has not been determined.

In elderly patients with dementia on the background of the combined administration of risperidone and furosemide, an increased mortality was also observed in comparison with patients receiving monotherapy with these drugs. This is evidenced by data from two of the four ongoing clinical trials. The combined use of risperidone with other diuretics (mostly low-dose thiazide diuretics) was not accompanied by an increase in mortality.

Cerebrovascular side effects were observed significantly more frequently in patients with mixed or vascular dementia compared with patients with dementia due to Alzheimer's disease. Therefore, risperidone is not recommended for any type of dementia other than that associated with Alzheimer's disease.

The patient's condition during the treatment period should be constantly assessed, as well as the need to continue taking the drug.

With orthostatic hypotension, the dose of Torendo is adjusted. It is recommended to consider the possibility of their reduction in the development of arterial hypotension.

In the first few months of therapy, patients with a history of drug-induced leukopenia / neutropenia or a clinically significant decrease in leukocyte count should be monitored. If the development of the first signs of a clinically significant decrease in the number of leukocytes is observed, and there are no other causative factors, therapy is discontinued.

Patients with clinically significant neutropenia should be closely monitored for fever or other symptoms of infection, and should receive appropriate therapy immediately if such symptoms occur. In severe neutropenia, Torendo is discontinued until the leukocyte count is restored.

The development of objective or subjective symptoms indicating tardive dyskinesia is a reason to consider the advisability of canceling Torendo.

Taking antipsychotic drugs can contribute to the development of neuroleptic malignant syndrome. If the patient has objective or subjective symptoms of the syndrome, Torendo is immediately canceled.

Consideration should be given to the possible aggravation of Parkinson's disease with risperidone therapy.

In diabetes mellitus, it is important to regularly monitor the serum glucose concentration.

During the period of taking the pills, body weight increases significantly, therefore, regular monitoring of the patient's weight is required.

Preclinical studies have shown that the use of risperidone may be accompanied by antiemetic effects. It should be borne in mind that this effect can mask the symptoms of an overdose of certain drugs or pathologies such as a brain tumor, Reye's syndrome and intestinal obstruction.

There are reports of the development of venous thromboembolism during treatment with antipsychotic drugs. In this regard, before the start and during the period of taking Torendo, all possible risk factors for the development of thromboembolic complications should be identified and preventive measures should be taken.

During the operation for cataracts in patients taking Torendo, the development of intraoperative syndrome of flabby iris was noted. The syndrome during and after surgery can increase the risk of ocular complications. The ophthalmologist should be warned in advance about taking the drug now or in the past. Since the potential benefit of drug withdrawal prior to cataract surgery has not been established, it is important to balance the potential benefit versus the likely risk of withdrawal.

Influence on the ability to drive vehicles and complex mechanisms

To a small or moderate degree, the drug can affect the ability to drive vehicles and mechanisms. During the period of Torendo therapy, patients should refrain from driving and conducting potentially hazardous activities until their individual sensitivity to the drug has been clarified.

Application during pregnancy and lactation

According to the instructions, Torendo is prescribed with caution during pregnancy, assessing the potential risks to the fetus and the benefits to the mother. If it is necessary to discontinue therapy during pregnancy, the drug is withdrawn gradually.

In animal studies, it was found that risperidone and its metabolite can pass into breast milk. It is also known that in small quantities they penetrate into the breast milk of lactating women taking the drug. On this basis, the appointment of Torendo during breastfeeding is made taking into account the possible risks to the child, although there is no information about side effects in infants whose mothers take the drug during lactation.

Pediatric use

The use of the drug is contraindicated in children under the age of 13 for the treatment of schizophrenia and persistent aggression in the structure of conduct disorder and under 10 years for the treatment of manic episodes associated with bipolar disorder.

Prior to the appointment of Torendo, children and adolescents with intellectual disabilities are thoroughly assessed in order to identify the social and physical causes of aggressive behavior.

In children and adolescents, the sedative effect of the drug should be closely monitored as it may affect learning ability. Changing the time of taking Torendo can reduce the effect of sedation on the attention of this patient population.

Oral intake of risperidone was associated with an increase in mean weight and body mass index. In the course of long-term studies, changes in height were within the expected age norms. The effect of prolonged drug therapy on sexual development and growth is not fully understood.

Since prolonged hyperprolactinemia can affect growth and puberty in children and adolescents, clinical assessment of hormonal status should be carried out regularly throughout treatment, including measurement of height, weight, monitoring of sexual development, menstrual cycle and other likely prolactin-dependent effects.

During the period of taking Torendo, it is important to regularly conduct an examination to identify extrapyramidal symptoms and other movement disorders.

With impaired renal function

The ability to eliminate the active antipsychotic fraction of risperidone with impaired renal function is lower than with normal organ function.

Torendo is prescribed with caution in severe renal failure. Apply ½ of the recommended initial and maintenance dose as indicated; the dose increase is carried out more slowly.

For violations of liver function

In case of impaired liver function, the concentration of the free fraction of risperidone in the blood plasma increases.

The drug is prescribed with caution in severe liver failure. Apply ½ of the recommended initial and maintenance dose of Torendo as indicated; the dose increase is carried out more slowly.

Use in the elderly

In elderly patients with cerebrovascular dementia, the drug is used with caution.

Drug interactions

There are no data on the interaction of Torendo with other drugs.

When used together, risperidone may reduce the effectiveness of levodopa and other dopamine agonists.

The development of clinically significant arterial hypotension is observed when Torendo is taken in combination with antihypertensive drugs.

Effect of drugs / substances on risperidone in combination therapy:

• carbamazepine, other inducers of the CYP3A4 isoenzyme and P-glycoprotein: reduce the concentration of its active antipsychotic fraction in blood plasma;
• paroxetine, fluoxetine, other inhibitors of the isoenzyme CYP2D6 (presumably): may increase its concentration in blood plasma and, to a lesser extent, the concentration of its active antipsychotic fraction;
• verapamil: increases its concentration in blood plasma;
• some β-blockers, tricyclic antidepressants, phenothiazines: can increase its concentration in blood plasma, but do not affect the concentration of its active antipsychotic fraction;
• ranitidine, cimetidine: increase its bioavailability, minimally affect the concentration of its active antipsychotic fraction;
• paliperidone: may increase the concentration of its active antipsychotic fraction.

Analogs

Torendo's analogues are: Speridan, Risset, Risperidone, Rispaxol, Risdonal, Ridonex, Rezalen, Leptinorm.

Terms and conditions of storage

Store in a place protected from light and moisture at temperatures up to 25 ° C. Keep out of the reach of children.

The shelf life is 5 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Torendo

According to reviews, Torendo is an effective drug that helps to cope with severe mental conditions. Among the disadvantages are the presence of a large number of contraindications and side effects.

Price for Torendo in pharmacies

Approximate price of Torendo film-coated tablets (20 pcs per pack):

• 1 mg each - 270 rubles;
• 2 mg - 495 rubles;
• 3 mg each - 733 rubles;
• 4 mg each - 1064 rubles.

Torendo: prices in online pharmacies

Drug name Price Pharmacy

Torendo 1 mg film-coated tablets 20 pcs. 156 r Buy

Torendo tablets p.o. 1mg 20 pcs. RUB 185 Buy

Torendo Ku-tab 0.5 mg lozenges 30 pcs. 278 r Buy

Torendo 2 mg film-coated tablets 20 pcs. 299 r Buy

Torendo KU-Tab tablets for rassas. 0.5mg 30 pcs. 301 RUB Buy

Torendo Ku-tab 2 mg lozenges 30 pcs. RUB 319 Buy

Torendo Ku-tab 1 mg lozenges 30 pcs. 386 r Buy

Torendo 3 mg film-coated tablets 20 pcs. 399 RUB Buy

Torendo 4 mg film-coated tablets 20 pcs. 456 r Buy

Torendo Ku-tab tab. dispersion in the oral cavity 1mg 30 pcs. RUB 481 Buy

Torendo tablets p.o. 4mg 20 pcs. RUB 517 Buy

See all offers from pharmacies

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!